Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven for PNALD in Infants
NCT02370251Phase 3Completed
- Sponsor
- University of Oklahoma
- Start
- Jun 2015
- Primary completion
- Sep 2018
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD), sponsored by University of Oklahoma. Primary endpoint: Resolution of Cholestasis for Subjects Who Received Omegaven at 3 months. Started Jun 2015; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT02370251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370251.